According to the report, the global cell line and membrane market is estimated to generate $4.5 billion in 2021 and $10.6 billion by 2031, witnessing a CAGR of 8.8% from 2021 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.
Drivers and Opportunities
Rise in the prevalence of cancer and chronic diseases, increase in the geriatric population, growth in the adoption of regenerative medicines, a surge in investments in R&D by pharmaceutical and biotechnology companies, rise in development & demand for monoclonal antibodies, increase in production of vaccines, and technological innovations in cell lines and the membrane fuel the growth of the global cell line and membrane market. However, a strict regulatory framework coupled with the time-consuming process for the development of stable lines might hinder the market growth. On the other hand, low-income countries lacking access to basic healthcare and an increase in the risk of pandemic and communicable diseases present new opportunities in the market in the coming years.
Impact of Covid-19 on Cell Line and Membrane Market-
- The outbreak of the Covid-19 pandemic positively impacted the cell line and membrane market, due to the growing number of pet adoption during the lockdown and rise in the demand for animal health insurance.
- Moreover, many initiatives taken by the government to reduce disease prevalence among animals led to the growth of cell Line and membrane market. Launch of advanced products for the treatment of animals with minimal side effects boosted the market growth.
- Furthermore, a rise in research and development activities increased the approval of new devices, testing procedures and drugs, thus offering opportunities for the key players to develop advanced devices for the quick diagnosis and prevention from such diseases.
The media and reagents segment to dominate the market in terms of revenue during the forecast period
Based on products, the media and reagents segment contributed to the largest share of more than half of the global cell line and membrane market in 2021, and is expected to rule the roost during the forecast period. Moreover, the same segment is projected to witness the fastest CAGR of 9.2% from 2021 to 2031. The growth of this segment is attributed to rise in the prevalence of cancer and chronic diseases, rise in number of R&D activities globally, and increasing product approval and new product launches.
The mammalian cell line segment to maintain its lion’s share during the forecast period
Based on source, the mammalian cell line segment held the largest share of more than two-thirds of the global cell line and membrane market in 2021, and is expected to maintain a prominent growth during the forecast period. The dominance of this segment can be attributed to the rise in the demand for recombinant protein development through mammalian cell. However, the non-mammalian cell line segment is likely to exhibit the highest CAGR of 9.8% in 2031, owing to the increase in adoption of regenerative medicines, rise in prevalence of cancer across the globe, and surge in investments in R&D by pharmaceutical and biotechnology companies.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/14227
The recombinant cell lines segment to garner the largest revenue by 2031
Based on type, the recombinant cell lines segment was the largest market in 2021, accounting for more than one-third of the global cell line and membrane market, and is likely to lead the trail throughout the forecast period. This is due to the rise in the demand for recombinant cell line which owes greatly to technological advancements in expression vector design, cell line engineering, and clone screening. However, the primary cell lines segment is anticipated to manifest the fastest CAGR of 10.1% during the forecast period, owing to rise in adoption of primary cell line for the production and manufacturing of bio-therapeutics such as vaccines, monoclonal antibodies, and fusion proteins.
North America to garner the largest revenue by 2031
Based on region, North America was the largest market in 2021, accounting for around two-fifths of the global cell line and membrane market, and is likely to lead the trail throughout the forecast period. This is due to the increase in the healthcare expenditure, a rise in the prevalence of cancer, growing demand for cell line for the development of therapeutic monoclonal antibodies and novel antibodies, and the presence of major players in this region. However, Asia-Pacific is anticipated to manifest the fastest CAGR of 9.8% during the forecast period, due to the rise in prevalence of chronic diseases, an increase in the geriatric population and an emerging economy in the region.
Leading Market Players
- Advanced Instruments LLC
- AGC Biologics
- Cytiva Lifesciences
- Sartorius Cellgenix Gmbh
- Premas Biotech
- Selexis SA
- Lonza
- Samsung Biologics
- PromoCell
- Thermofisher Scientific Inc.
- Imegenex IndiaPvt. Ltd.
- ProBioGen
0 Comments